Financial Performance - Remitly achieved \$412 million in revenue for 2Q25, a 34% year-over-year increase[10] - The company reported GAAP net income of \$65 million for 2Q25[10] - Adjusted EBITDA for 2Q25 was \$64 million, representing a 16% adjusted EBITDA margin[10] - Send volume grew by 40% year-over-year to reach \$185 billion in 2Q25[28] - Quarterly active customers increased by 24% year-over-year, totaling 85 million[28] Future Outlook - Remitly projects full-year 2025 revenue to be between \$1610 billion and \$1620 billion, indicating a 27% to 28% year-over-year growth[39] - The company anticipates full-year 2025 adjusted EBITDA to be between \$225 million and \$230 million[39] - For 3Q 2025, Remitly expects revenue to range from \$411 million to \$413 million, a 22% to 23% year-over-year increase[42] - 3Q 2025 adjusted EBITDA is projected to be between \$53 million and \$55 million[42] Strategic Initiatives - Remitly is expanding its total addressable market (TAM) from \$2 trillion to \$22 trillion with Remitly Business[15]

Company Overview - ADENTRA's sales reached $22 billion in 2024[9] - Adjusted EBITDA was $184 million in 2024[9] - Free cash flow amounted to $858 million in 2024[9] - The company serves over 60000 customers and partners with over 2500 suppliers[9] - ADENTRA has a diversified customer base, with 55% being industrial manufacturers, 31% pro dealers, and 14% home centers[10] Market Position and Growth - ADENTRA operates in a $43 billion combined market opportunity across various product categories[25] - The company's current market share is 5%[25] - ADENTRA has grown through acquisitions, adding $17 billion in sales since 2010[34] - The company has 86 locations[9] Financial Performance and Strategy - Adjusted EBITDA has increased at a 20% CAGR over the past 10 years[28] - The company aims for a gross profit margin of over 20% and an adjusted EBITDA margin of 8-10%[48] - ADENTRA targets a leverage ratio between 20-30x adjusted EBITDA and 10x working capital[54] - The company's free cash flow yield is 127%[54]

Financial Performance - Revenue reached $104.6 million[22], reflecting a 12% year-over-year increase[23] - Constant Currency revenue growth was 10%[23] - Net loss was ($2.0 million)[22] - Adjusted EBITDA was $31.9 million[22], a 21% increase compared to the prior year[39] - Adjusted diluted EPS was $0.07[22] Bookings and Retention - Net bookings for the quarter were $112.0 million[29] - Trailing twelve months (TTM) bookings reached $470.8 million[29] - Software Net Retention Rate (NRR) was 107.6%[35] Guidance - The company reiterated its FY 2025 revenue guidance of $415-$425 million[48] - Adjusted EBITDA margin is expected to be 30-32%[48] - Adjusted diluted EPS is projected to be $0.42-$0.46[48]

Financial Performance - ACIC's Non-GAAP Core Income for Q2 2025 increased by $7.2 million (+36.4%) year-over-year to $26.8 million ($0.54 per share) from $19.6 million ($0.40 per share) [9] - Net premiums earned grew by $15.0 million (+23.8%) year-over-year to $78.4 million [9] - The combined ratio decreased to 60.6% from 64.9% in the prior year, and the Non-GAAP underlying combined ratio decreased to 62.2% from 66.4% [9] - Stockholders' equity increased by $56.6 million from December 31, 2024, to $292.3 million, or $6.00 per share [9] - Net income from continuing operations increased by $8.9 million (+46.6%) year-over-year to $28.0 million [14] Balance Sheet & Investment - Total Assets reached $1.35 billion as of June 30, 2025 [6] - Total Equity was $292.3 million as of June 30, 2025 [6] - Cash & investments increased by 34.3% from December 31, 2024, to $726.243 million [15] - Total Cash & Investments increased by 27.7% from Mar. 31, 2025 to $726.243 million [17] Other Highlights - The company completed its Core CAT reinsurance program effective June 1, 2025, with a risk-adjusted decrease of -12.4% [9] - ACIC was upgraded to investment grade status (BBB-) by KBRA on 7.21.25, saving approximately $1.5 million per year in interest expense [9]

Q2 2025 Financial Performance - Net income reached $6.9 million, a year-over-year increase of $38 million[13] - Earnings per share (EPS) amounted to $0.14, up $0.92 year-over-year[13] - Return on equity (ROE) achieved 7.4%, a 41 percentage point increase year-over-year[13] - Adjusted EPS was $0.31, compared to $0.08 in Q2 2024[14] - Adjusted ROE was 16%, versus 3.5% in Q2 2024[14] - Adjusted EBITDA totaled $31 million, a year-over-year increase of $1 million[14] Credit Quality and Operating Efficiency - The net charge-off (NCO) rate was 11.9%, a decrease of 41 basis points year-over-year, with dollar net charge-offs down by 6% year-over-year[14] - The 30+ day delinquency rate was 4.4%, a decrease of 54 basis points year-over-year[14] - Operating expenses (OpEx) amounted to $94.4 million, a 13% year-over-year decline[14] - Q2 risk adjusted net interest margin ratio improved by 192 bps Y/Y to 16.3%[16] - Q2 Adjusted OpEx ratio improved by 46 bps Y/Y to 13.3%[16] Strategic Focus and Future Outlook - The company is raising its 2025 adjusted EPS expectations by 8% at the midpoint[11] - Full-year 2025 adjusted EPS guidance of $1.20-$1.40 reflects 67%-94% growth[14] - The company anticipates full-year 2025 operating expenses of $380 million, a $10 million reduction from prior expectations and a $30 million reduction from 2024's $410 million[14] - The company expects approximately 10% full-year 2025 loan origination growth[14] - Secured personal loan portfolio grew 58% year-over-year in Q2, reaching 7% of owned portfolio[16]

Financial Performance - Revenue decreased from $26.7 million in Q2 2024 to $25.3 million in Q2 2025[3] - Adjusted EBITDA decreased from $6.8 million in Q2 2024 to $4.1 million in Q2 2025[3] - Adjusted EBITDA margin decreased from 25% to 16%[22] - Net income decreased from $2.902 million in Q2 2024 to $1.034 million in Q2 2025[21] Loan Origination - Total certs decreased from 28,963 in Q2 2024 to 26,522 in Q2 2025[3] - Facilitated loan origination volume decreased from $819.3 million in Q2 2024 to $783.3 million in Q2 2025[18, 20] - Average loan size increased from $28,286 in Q2 2024 to $29,535 in Q2 2025[18, 20] Channel and Vehicle Mix - OEM certs decreased from 23.9% of total in Q2 2024 to 11.1% in Q2 2025[6, 10] - CU/Bank certs increased from 76.1% of total in Q2 2024 to 88.9% in Q2 2025[6] - New vehicle certs as a percentage of total increased slightly from 12.7% to 13.1%[10, 20] - Used vehicle certs accounted for 86.9% of total certs in Q2 2025[10, 20]

Financial Performance - Net Revenue increased by 14% compared to 2024[9] - Subscription Revenue increased by 16%[8, 17] - Adjusted EBITDA reached R$462 million, an 8% increase from R$428 million in 2024[11, 12] - Free Cash Flow increased by 147% to R$224 million compared to R$90 million in 2024[14, 34] - Adjusted EBITDA margin decreased by 1.6 percentage points to 31.1% compared to 32.7% in 2024[12, 28] Revenue Breakdown - Subscription revenue cycle to date increased by 16%[17] - Non-subscription revenue cycle to date increased by 11%[17] - B2G (Business-to-Government) revenue cycle to date decreased by 28%[17] Margin Analysis - Gross margin decreased by 0.6 percentage points[24] - Commercial expenses slightly increased but remained stable near 17% of net revenue[24, 26] - Adjusted G&A expenses decreased due to operational efficiencies and workforce optimization[24, 27] Debt and Cash Flow - Net Debt decreased by R$123 million cycle to date[47] - LTM (Last Twelve Months) FCF / LTM Adjusted EBITDA conversion improved by 25.8 percentage points to 57.7% compared to 31.9% in 2024[15, 34]

Financial Performance - Q2 2025 - Total revenue reached $811 million in Q2 2025, a 16% year-over-year increase[5] - Adjusted EBITDA for Q2 2025 was $138 million, up 26% year-over-year[5] - Core revenue also grew by 16% in Q2 2025[7] - Screening revenue increased by 18% from $532 million in Q2 2024 to $628 million in Q2 2025[8] - Precision Oncology core revenue increased by 9% from $165 million in Q2 2024 to $179 million in Q2 2025[8] Profitability and Cash Flow - Adjusted EBITDA margin improved to 17% in Q2 2025, an increase of 130 basis points[11] - Free cash flow was $46 million[11] Updated 2025 Guidance - Total revenue guidance updated to $3.13 billion - $3.17 billion, an increase of $55 million at the midpoint[13] - Screening revenue guidance updated to $2.44 billion - $2.47 billion, an increase of $48 million at the midpoint[13] - Adjusted EBITDA guidance updated to $455 million - $475 million, an increase of $25 million at the midpoint[13] Cost Savings Initiatives - A multi-year productivity program aims for $150 million in annual run-rate cost savings by 2026[16, 17]

Company Overview - The Honest Company was launched in 2012 with a focus on clean ingredients and sustainability[15] - The company's mission is to challenge ingredients, ideals, and industries to protect loved ones[16] - The Honest Standard includes banning over 3,500 ingredients and utilizing in-house labs for innovative formulas[18, 19] - The company is the 1 natural brand in baby personal care[20] and baby wipes[22] Financial Performance - In 2024, revenue reached $378 million, a 10% increase year-over-year[38] - Gross margin in 2024 was 38%, representing a 900 bps improvement year-over-year[38] - Adjusted EBITDA for 2024 was $26 million, a $37 million increase year-over-year[38] - The company had $75 million in cash and $0 debt at the end of 2024[29] - Q1 2025 revenue was $97 million, a 13% increase year-over-year[41] - Q2 2025 revenue was $93 million, a 0.4% increase year-over-year[44] Growth Strategy - The company is focused on brand maximization, margin enhancement, and operating discipline[28] - Household penetration has increased by 20% since 2021[24] - The company aims to expand distribution by increasing total distribution points[59] - There is a large runway for growth into more doors, with approximately 45,000 doors selling Honest products compared to a leading competitor's ~90,000 doors[66]

Financial Performance - Q2 2025 - Total company net sales reached $31.1 million, a 37% year-over-year increase[10] - Tru Niagen® net sales were $22.7 million, representing a 22% year-over-year increase[10] - Niagen® ingredient sales surged to $7.4 million, marking a 135% year-over-year increase[10] - Gross margin improved to 65.0%, up 480 basis points year-over-year[10] - Net income was $3.6 million, or $0.05 earnings per share, a $3.6 million year-over-year increase[10] - Adjusted EBITDA reached $5.0 million, a $3.5 million year-over-year increase[10] Financial Position - Cash provided from operations year-to-date was $9.1 million, with a cash balance of $60.5 million and no debt[10] Sales Mix - Q2 2025 - E-commerce accounted for 57% of net sales, while Watson's & Other B2B represented 25%[26] - Food-grade Niagen® contributed 14% to net sales, and Analytical Reference Standards & Services accounted for 3%[26] - Other Ingredients made up 1% of net sales[26] 2025 Outlook - The company anticipates net sales growth between 22% and 27% year-over-year[10] - Sales and marketing expenses are expected to increase in absolute dollars but decrease as a percentage of net sales year-over-year[10]